Heron Therapeutics: A Court Decision, a Balance-Sheet Reset, and Strategic Alternatives
The second-quarter 2026 call for Heron Therapeutics was not the typical commercial update. Net revenue of $37.7 million did rise from the first quarter, but management's tone was dominated by a single event: a U.S. District Court decision that changed the company's outlook. As CEO Craig Collard put it, “Net revenue for the quarter was $37.7 million. That is growth from the first quarter, but it is below what we expected of ourselves.” — Craig Collard, Chief Executive Officer · 2026-08-10 The gap was not just about sales execution; it was about a patent ruling that threatens the company's largest product, CINVANTI.
The Court Decision That Changed Everything
The June ruling by the Delaware court regarding certain patents covering court decision CINVANTI forced Heron to make a stark choice. In response, the company filed an appeal, but it also began preparing for potential generic competition to CINVANTI. Management explicitly acknowledged that a generic launch could occur sooner than previously modeled. Collard explained, “We took a very conservative approach with how we looked at the generic launch... I do think this may take a bit longer than maybe we modeled out.” — Craig Collard, Chief Executive Officer · 2026-08-10 Yet the guidance withdrawal was blunt: CFO Ira Duarte said, “We are withdrawing our full year 2026 guidance of $173 million to $183 million in net product sales and $10 million to $20 million in adjusted EBITDA.” — Ira Duarte, Executive Vice President · 2026-08-10 The company no longer feels it can forecast an annual number when the timing and terms of generic entry are unknowable.
Balance-Sheet Reset
To weather the uncertainty, Heron immediately negotiated an amendment to its credit facility with Hercules. The amendment reduced principal—$13.5 million paid at execution, plus a potential additional $4 million by September 15—and reset financial covenants through 2027.
This was a necessary step given the company's leverage profile. In the prior quarter, Liabilities to assets stood at 96.3%, and the new agreement provides a principal reduction and a clearer runway through December 2027.First, we reset the balance sheet. As we disclosed today, we amended our credit facility with Hercules. When the decision from the U.S. District Court for the District of Delaware regarding certain patents covering CINVANTI changed the outlook for the company, we went to our lender.
Commercial Strengths Amid the Turmoil
Despite the corporate disruptions, the acute-care franchise continued to grow. ZYNRELEF revenue rose 35% year-over-year, with Average daily units up 19%, and APONVIE grew 74% to reach a 23% share of the surgical NK-1 segment. Even CINVANTI held steady quarter-over-quarter at $21.8 million, though it declined 10% year-over-year against branded competition. The company paused its planned sales-force expansion and is "holding spending tightly," but Mark Hensley noted that ZYNRELEF's slower-than-planned quarter was more about market seasonality than product demand: “we still continue to make progress on P&T wins throughout the quarter... really, it's just about time of pull-through.” — Mark Hensley, Senior Vice President, Finance and Chief Financial Officer · 2026-08-10 This resilience in acute care is the counterweight to the oncology franchise's patent risk.
Strategic Alternatives
Perhaps the most consequential signal came at the end of the prepared remarks: the company is "considering strategic alternatives" with no timetable. This is a departure from the tone on prior calls, such as May 2026, when management was still outlining confident growth drivers for the year. In that call, Mark Hensley had said, “we certainly think that will help our share of voice and really kind of build upon the foundation that we've already built.” — Mark Hensley, Unknown · 2026-05-11 Now, the same executives are managing for a potential sale or other transaction. The amended credit agreement reflects this shift, and the company has strategic alternatives explicitly on the table for the first time.
The market has already voted: HRTX stock has fallen more than 60% in the last 90 days, and the company trades at a price-to-revenue of just ~1x. The decision to pull guidance and restructure debt indicates that the management team is bracing for a fundamentally different competitive landscape. Whether the acute-care products can outgrow the CINVANTI erosion remains the key question for 2027 and beyond.